Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy

بواسطة Jan Walewski, Andrzej Hellmann, Noppadol Siritanaratkul, Guner Hayri Ozsan, Muhit Ozcan, Suporn Chuncharunee, Ai Sim Goh, Wojciech Jurczak, Jan Koren, Ewa Paszkiewicz-Kozik, Bingxia Wang, Shalini Singh, Dirk Huebner, Andreas Engert, Bastian von Tresckow
منشور في 2019